Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.
2.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ; American Society of Clinical Oncology..

J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Review.

PMID:
20625130
3.

Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.

Singh Ranger G.

J Clin Pharm Ther. 2005 Aug;30(4):313-7. Review. Erratum in: J Clin Pharm Ther. 2005 Oct;30(5):496. Sing Ranger, G [corrected to Singh Ranger, G].

PMID:
15985044
4.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Review.

PMID:
16098456
5.
6.

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A.

J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Review.

7.

Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.

Pritchard KI.

J Clin Oncol. 2005 Aug 1;23(22):4850-2. No abstract available.

PMID:
16009956
8.
9.

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.

J Clin Oncol. 2005 Aug 1;23(22):5178-87.

PMID:
15998905
10.
11.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group., Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

12.
14.

Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?

Tang SC.

Cancer Invest. 2008 Jun;26(5):481-90. doi: 10.1080/07357900701781812. Review.

PMID:
18568770
15.

Adjuvant endocrine therapy for postmenopausal women with early breast cancer.

Ingle JN.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1031s-1036s.

17.

Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.

Goss PE.

Semin Oncol. 2006 Apr;33(2 Suppl 7):S8-12.

PMID:
16730271
18.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
19.

[Aromatase inhibitors in the adjuvant therapy of breast cancer].

Bauerschlag D, Schem C, Maass N, Jonat W.

Gynakol Geburtshilfliche Rundsch. 2005 Jun;45(3):132-6. German.

PMID:
15990437
20.
Items per page

Supplemental Content

Support Center